Guardant Health
Guardant Health is a leading precision oncology company that develops advanced blood and tissue tests to provide critical insights across all stages of cancer care. The company leverages liquid biopsy technology, real-world data, and AI analytics to improve patient outcomes through early cancer screening, recurrence monitoring, and therapy selection for advanced-stage tumors.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Precision Oncology Testing
primaryDiagnostic and monitoring services for patients across the cancer care continuum, from early-stage recurrence detection to advanced-stage therapy selection.
Guardant360 CDx, Guardant360 Liquid, Guardant360 Tissue, Guardant Reveal, Guardant360 LDT
Oncologists, Hospitals, Cancer Centers, Patients
Development Services and Biopharmaceutical Collaborations
majorCollaborative services and data platforms provided to pharmaceutical companies to accelerate drug development and clinical trial enrollment.
GuardantOMNI, GuardantINFINITY, GuardantINFORM, Smart Platform, InfinityAI
Biopharmaceutical Companies, Clinical Researchers
Cancer Screening
moderateBlood-based screening tests designed for early detection of cancer in average-risk populations and multi-cancer detection research.
Shield, Shield MCD
Primary Care Physicians, Average-risk Adults, Payors
Segment Financials
Oncology — Total Revenue
View metricReportable Segment — Cost of precision oncology testing
View metricReportable Segment — Research and development expense
View metricBiopharma and data — Total Revenue
View metricReportable Segment — Sales and marketing expense
View metricScreening — Total Revenue
View metricBusiness Overview
Competitive Position
A pioneer in liquid biopsy technology and the first to receive FDA approval for a comprehensive liquid biopsy companion diagnostic.
Geographies
United States, Global
Customer Segments
Healthcare Providers, Biopharmaceutical Companies, Patients, Medicare
Upstream Dependencies
Next-generation sequencing equipment manufacturers, Laboratory chemical and reagent suppliers, Cloud computing infrastructure providers
Downstream Customers
Oncology clinics, Primary care networks, Pharmaceutical R&D departments, Health insurance companies
Competitors & Partners
Competitors
Guardant Health FAQ
Common questions about Guardant Health
Guardant Health is a leading precision oncology company that develops advanced blood and tissue tests to provide critical insights across all stages of cancer care. The company leverages liquid biopsy technology, real-world data, and AI analytics to improve patient outcomes through early cancer screening, recurrence monitoring, and therapy selection for advanced-stage tumors.
Guardant Health (GH) has a market capitalization of $17.2B and trades on NASDAQ.
Guardant Health generated $1.1B in trailing twelve-month revenue with a net loss of $433.2M, representing a net margin of -40.1%. Gross margin stands at 64.9%, with free cash flow of -$237.1M. These figures are based on the Q1 2026 filing.
Guardant Health's key competitors include Natera, Illumina, Grail, and others. These companies compete in similar markets and product categories.
Guardant Health has approximately 1,779 employees.